ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

Overexpression of the prosurvival Bcl-2 family members (Bcl-2, Bcl-xL, and Mcl-1) is commonly associated with tumor maintenance, progression, and chemoresistance. We previously reported the discovery of ABT-737, a potent, small-molecule Bcl-2 family protein inhibitor. A major limitation of ABT-737 is that it is not orally bioavailable, which would limit chronic single agent therapy and flexibility to dose in combination regimens. Here we report the biological properties of ABT-263, a potent, orally bioavailable Bad-like BH3 mimetic (K(i)'s of <1 nmol/L for Bcl-2, Bcl-xL, and Bcl-w). The oral bioavailability of ABT-263 in preclinical animal models is 20% to 50%, depending on formulation. ABT-263 disrupts Bcl-2/Bcl-xL interactions with pro-death proteins (e.g., Bim), leading to the initiation of apoptosis within 2 hours posttreatment. In human tumor cells, ABT-263 induces Bax translocation, cytochrome c release, and subsequent apoptosis. Oral administration of ABT-263 alone induces complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 exhibits modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. These data provide the rationale for clinical trials evaluating ABT-263 in small-cell lung cancer and B-cell malignancies. The oral efficacy of ABT-263 should provide dosing flexibility to maximize clinical utility both as a single agent and in combination regimens.

[1]  M. Amiot,et al.  A pivotal role for Mcl-1 in Bortezomib-induced apoptosis , 2008, Oncogene.

[2]  Laurent Bélec,et al.  Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis , 2007, Proceedings of the National Academy of Sciences.

[3]  R. Lock,et al.  Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. , 2007, Blood.

[4]  A. Strasser,et al.  Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia , 2007, Cell Death and Differentiation.

[5]  W. Hiddemann,et al.  BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts , 2007, Leukemia.

[6]  P. Greipp,et al.  ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells , 2007, Leukemia.

[7]  R. Bataille,et al.  Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. , 2007, Cancer research.

[8]  C. Tse,et al.  Bcl-2 family proteins are essential for platelet survival , 2007, Cell Death and Differentiation.

[9]  E. Bröcker,et al.  Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma , 2007, British Journal of Cancer.

[10]  S. Fesik,et al.  ‘Seed’ analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737 , 2007, Oncogene.

[11]  N. Munshi,et al.  A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma , 2007, Oncogene.

[12]  P. Ekert,et al.  Programmed Anuclear Cell Death Delimits Platelet Life Span , 2007, Cell.

[13]  G. Giaccone,et al.  Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non–small cell lung cancer cell line NCI-H460 , 2007, Molecular Cancer Therapeutics.

[14]  C. Tse,et al.  Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. , 2007, Cancer research.

[15]  Mary K Joseph,et al.  Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. , 2007, Journal of medicinal chemistry.

[16]  P. Dent,et al.  Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. , 2007, Cancer research.

[17]  S. Trudel,et al.  The Bcl-2 Family Protein Inhibitor, ABT-737, Has Substantial Antimyeloma Activity and Shows Synergistic Effect with Dexamethasone and Melphalan , 2007, Clinical Cancer Research.

[18]  Michael T. Certo,et al.  Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. , 2007, The Journal of clinical investigation.

[19]  A. Petros,et al.  Design, synthesis, and computational studies of inhibitors of Bcl-XL. , 2006, Journal of the American Chemical Society.

[20]  C. Scott,et al.  The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. , 2006, Cancer cell.

[21]  John Calvin Reed,et al.  Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. , 2006, Cancer cell.

[22]  J C Reed,et al.  Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins , 2006, Cell Death and Differentiation.

[23]  S. Armstrong,et al.  Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. , 2006, Cancer cell.

[24]  D. Green,et al.  Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. , 2006, Molecular cell.

[25]  P. Hajduk,et al.  Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. , 2006, Journal of medicinal chemistry.

[26]  Y. Matsuzaki,et al.  Enhancement of DNA topoisomerase I inhibitor–induced apoptosis by ursodeoxycholic acid , 2006, Molecular Cancer Therapeutics.

[27]  Stephen W. Fesik,et al.  Promoting apoptosis as a strategy for cancer drug discovery , 2005, Nature Reviews Cancer.

[28]  B. Bonavida,et al.  Rituximab-Induced Inhibition of YY1 and Bcl-xL Expression in Ramos Non-Hodgkin’s Lymphoma Cell Line via Inhibition of NF-κB Activity: Role of YY1 and Bcl-xL in Fas Resistance and Chemoresistance, Respectively1 , 2005, The Journal of Immunology.

[29]  M. Hendrix,et al.  Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. , 2005, Cancer research.

[30]  S. Lowe,et al.  Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. , 2005, Cancer research.

[31]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[32]  G. Cheng,et al.  Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. , 2005, Cancer research.

[33]  S. Korsmeyer,et al.  Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[34]  S. Joos,et al.  The role of Bcl-2 family members in tumorigenesis. , 2004, Biochimica et biophysica acta.

[35]  S. Korsmeyer,et al.  Cell Death Critical Control Points , 2004, Cell.

[36]  S. Ng,et al.  Development of a high-throughput fluorescence polarization assay for Bcl-x(L). , 2002, Analytical biochemistry.

[37]  S. Korsmeyer,et al.  BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. , 2001, Molecular cell.

[38]  W. Zong,et al.  BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. , 2001, Genes & development.

[39]  E. Frenkel,et al.  Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues , 2001, Expert opinion on pharmacotherapy.

[40]  Z. X. Wang,et al.  An exact mathematical expression for describing competitive binding of two different ligands to a protein molecule , 1995, FEBS letters.

[41]  A. Hagenbeek,et al.  The therapeutic use of rituximab in non-Hodgkin's lymphoma. , 2007, European journal of haematology. Supplementum.

[42]  E. Campo,et al.  The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. , 2006, Blood.

[43]  Cheol‐Min Park,et al.  Inhibitors of Anti-apoptotic Proteins for Cancer Therapy , 2005 .